Yahoo! Finance: Biotechnology Industry News: GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

100 Greatest Books on MP3 Get the 100 greatest books of all time preloaded on an MP3 player. Listen to the classics like Tom Sawyer, Moby Dick, Pride & Prejudice & 97 more. Less than $1 each. From our sponsors

GSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint Sep 5th 2013, 06:05 [Business Wire] - Agenus Inc. today announced that GlaxoSmithKline's DERMAi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 cancer immunotherapeuticii trial, which contains Agenus'QS-21 Stimulon® adjuvantiii, a component of GSK's novel adjuvant system AS15, did not meet its first co-primary endpoint.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions